Literature DB >> 20602613

Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy.

Christian Hammer1, Peter A Fasching, Christian R Loehberg, Claudia Rauh, Arif B Ekici, Sebastian M Jud, Mayada R Bani, Matthias W Beckmann, Reiner Strick, Beate Niesler.   

Abstract

AIMS: Serotonin (5-hydroxytryptamine 3; 5-HT(3)) receptors are involved in chemotherapy-induced nausea and vomiting (CINV), and 5-HT(3) antagonists are part of the 'gold standard' antiemetic treatment during chemotherapy. We investigated the correlation of common variants in 5-HT(3) receptor subunit genes with the occurrence of CINV. MATERIALS &
METHODS: A total of 110 previously characterized chemotherapy-naive women with primary breast cancer treated with anthracycline-containing chemotherapy served as a study group for mutational analysis by direct sequencing. Eight common SNPs in the 5-HT(3) receptor genes, HTR3A, HTR3B, HTR3D and HTR3E, were selected for association analysis.
RESULTS: A nonsynonymous variant in HTR3D, p.G36A (rs6443930), was found to be over-represented in nonresponders, assuming a log-additive inheritance model (p = 0.048). Cox proportional regression analysis resulted in a hazards ratio of 0.36 for homozygous carriers of the C allele to vomit within 24 h after first chemotherapy administration (p = 0.049).
CONCLUSION: Our data supports the hypothesis that 5-HT(3) receptors play an important role in the pathogenesis of CINV. Along with previously identified HTR3 polymorphisms, the HTR3D p.G36A variant could also contribute to facilitating individual risk predictions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20602613     DOI: 10.2217/pgs.10.67

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  8 in total

Review 1.  Genetic factors associated with pharmacotherapy and background sensitivity to postoperative and chemotherapy-induced nausea and vomiting.

Authors:  Piotr K Janicki; Shigekazu Sugino
Journal:  Exp Brain Res       Date:  2014-05-04       Impact factor: 1.972

Review 2.  A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting.

Authors:  Komal P Singh; Anand A Dhruva; Elena Flowers; Kord M Kober; Christine Miaskowski
Journal:  Crit Rev Oncol Hematol       Date:  2017-11-20       Impact factor: 6.312

3.  Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy.

Authors:  Mari Yokoi; Daiki Tsuji; Kenichi Suzuki; Yohei Kawasaki; Masahiko Nakao; Hideaki Ayuhara; Yuuki Kogure; Kazuhiko Shibata; Toshinobu Hayashi; Keita Hirai; Kazuyuki Inoue; Toshihiro Hama; Koji Takeda; Makoto Nishio; Kunihiko Itoh
Journal:  Support Care Cancer       Date:  2017-11-24       Impact factor: 3.603

Review 4.  Metagenomics and chemotherapy-induced nausea: A roadmap for future research.

Authors:  Sylvia L Crowder; Aasha I Hoogland; Taylor L Welniak; Elizabeth A LaFranchise; Kristen M Carpenter; Daneng Li; Daniel M Rotroff; Arshiya Mariam; Christine M Pierce; Stacy M Fischer; Anita Y Kinney; Thi Dong-Binh Tran; Farzaneh Rastegari; Donna L Berry; Martine Extermann; Richard D Kim; Danielle B Tometich; Jane C Figueiredo; Jameel Muzaffar; Shahla Bari; Kea Turner; George M Weinstock; Heather S L Jim
Journal:  Cancer       Date:  2021-10-13       Impact factor: 6.860

5.  Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors.

Authors:  Sonam Puri; Kelly A Hyland; Kristine Crowe Weiss; Gillian C Bell; Jhanelle E Gray; Richard Kim; Hui-Yi Lin; Aasha I Hoogland; Brian D Gonzalez; Ashley M Nelson; Anita Y Kinney; Stacy M Fischer; Daneng Li; Paul B Jacobsen; Howard L McLeod; Heather S L Jim
Journal:  Support Care Cancer       Date:  2018-03-15       Impact factor: 3.603

Review 6.  Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists?

Authors:  Morgan Trammel; Mary Roederer; Jai Patel; Howard McLeod
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

7.  Pharmacological evaluation of novel 5-HT3 receptor antagonist, QCM-13 (N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) as anti-anxiety agent in behavioral test battery.

Authors:  Deepali Gupta; Mahesh Radhakrishnan; Devadoss Thangaraj; Yeshwant Kurhe
Journal:  J Pharm Bioallied Sci       Date:  2015 Apr-Jun

Review 8.  Tapping into 5-HT3 Receptors to Modify Metabolic and Immune Responses.

Authors:  Helen Irving; Ilona Turek; Christine Kettle; Nor Yaakob
Journal:  Int J Mol Sci       Date:  2021-11-02       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.